Experimental Assessment of the Role of Acetaldehyde in Alcoholic Cardiomyopathy by Aberle II, Nicholas S. & Ren, Jun
 
 
 
 
 
Biological Procedures Online • Vol. 5 No. 1 • February 17, 2003 • www.biologicalprocedures.com 
 
 
© 2003. Biological Procedures Online.  Published in Biological Procedures Online under license from the author(s).  Copying,
printing, redistribution and storage permitted. 
Biol. Proced. Online 2003;5(1): 1-12. 
 
Experimental Assessment of the Role of Acetaldehyde in Alcoholic Cardiomyopathy 
 
Nicholas S. Aberle II
1 and Jun Ren
2* 
 
1Department of Pharmacology, Physiology and Therapeutics, University of North Dakota School of Medicine and Health Sciences. 
Grand Forks, ND 58203, USA 
 
2Division of Pharmaceutical Sciences, School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071-
3375. 
 
*To whom correspondence should be addressed. Dr. Jun Ren, Associate Professor, Division of Pharmaceutical Sciences, School of 
Pharmacy, University of Wyoming College of Health Sciences, P. O. Box 3375, Laramie, WY 82071-3375. Tel: (307)-766-6131, Fax: 
(307)-766-2953, E-mail: jren@uwyo.edu. 
 
Submitted: September 3, 2002; Revised: November 27, 2002; Accepted: December 12, 2002; Published: February 17, 2003 
 
Indexing terms: Heart, Transgenic, Myocyte, Acetaldehyde (ACA), Alcohol, Excitation-Contraction (E-C) coupling. 
 
 
ABSTRACT 
 
Alcoholism is one of the major causes of non-ischemic heart 
damage. The myopathic state of the heart due to alcohol 
consumption, namely alcoholic cardiomyopathy, is manifested 
by cardiac hypertrophy, compromised ventricular contractility 
and cardiac output. Several mechanisms have been postulated 
for alcoholic cardiomyopathy including oxidative damage, 
accumulation of triglycerides, altered fatty acid extraction, 
decreased myofilament Ca
2+ sensitivity, and impaired protein 
synthesis. Despite intensive efforts to unveil the mechanism 
and ultimate toxin responsible for alcohol-induced cardiac 
toxicity, neither has been clarified thus far. Primary candidates 
for the specific toxins are ethanol, its first and major metabolic 
product - acetaldehyde (ACA) and fatty acid ethyl esters. 
Evidence from our lab suggests that ACA directly impairs 
cardiac function and promotes lipid peroxidation resulting in 
oxidative damage. The ACA-induced cardiac contractile 
depression may be reconciled with inhibitors of Cytochrome P-
450 oxidase, xanthine oxidase and lipid peroxidation 
Unfortunately, the common methods to investigate the toxicity 
of ACA have been hampered by the fact that direct intake of 
ACA is toxic and unsuitable for chronic study, which is unable 
to provide direct evidence of direct cardiac toxicity for ACA. 
In order to overcome this obstacle associated with the chemical 
properties of ACA, our laboratory has used the chronic ethanol 
feeding model in transgenic mice with cardiac over-expression 
of alcohol dehydrogenase (ADH) and an in vitro ventricular 
myocyte culture model. The combination of both in vivo and in 
vitro  approaches allows us to evaluate the role of ACA in 
ethanol-induced cardiac toxicity and certain cellular signaling 
pathways leading to alcoholic cardiomyopathy. 
 
INTRODUCTION 
 
Chronic alcoholism has been demonstrated to cause 
detrimental damage to cardiac muscles leading to the 
development of alcoholic cardiomyopathy which accounts for 
~33% of all dilated cardiomyopathies (1). In patients with 
chronic alcoholism, the occurrence of cardiomyopathy of any 
kind, is increased to 50%, with a majority of these patients 
dying from heart failure. Alcoholic cardiomyopathy is 
manifested as cardiomegaly, disrupted myofibrillary 
architecture, reduced myocardial contractility, decreased 
ejection volumes and enhanced risk of stroke and hypertension 
(2, 3). Clinical studies have demonstrated that abstinence from 
alcohol prior to a certain stage may reverse this specific type of 
cardiomyopathy (3). There have been several hypotheses 
formulated regarding the pathogenesis of alcoholic 
cardiomyopathy, including direct and indirect cardiotoxicity of 
alcohol (4), accumulation of fatty acid ethyl esters (5), and the 
cardiac toxicity from the first oxidized metabolic product of 
ethanol, namely acetaldehyde (ACA) (6, 7, 8, 9). Nevertheless, 
none of these hypotheses have received convincing 
experimental support necessary to be fully validated.  
 
ACA, the first oxidized metabolic product of ethanol, has been 
considered a likelihood candidate toxin for the pathogenesis of 
alcoholic cardiomyopathy because its ability to concentrate in 
the heart and its high reactive property compared to ethanol 
(6). Our laboratory has shown that ACA may directly impair Aberle II and Ren    2 
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cardiac excitation-contraction (E-C) coupling and inhibit 
sarco(endo)plasmic reticulum (SR) Ca
2+ release function (7, 8, 
9, 10). However, the advancement of the ACA toxicity theory 
has been stalled due to the lack of suitable models to 
experimentally alter blood ACA and the technical constraints 
of ACA manipulation such as low boiling point and high 
chemical reactivity. These properties of ACA are likely to 
impose certain experimental and technical difficulties because 
of the ability of ACA to readily escape from solution or test 
chambers, and may cause an inaccuracy in the concentration of 
ACA, which would bias the experimental findings. Normally, 
ACA degrades very quickly (~ 5 times that of ethanol) via 
aldehyde dehydrogenase (ALDH) which maintains ACA at a 
low blood level (< 0.5 µM) following ingestion of 0.5 g/kg 
ethanol. Higher ACA levels (~ 2 µM) may be seen in 
alcoholics when given the same dose of ethanol, probably due 
to hepatic inhibition of ALDH activity (11). Furthermore, 
blood ACA levels may reach 30 - 500 µM following ethanol 
intoxication in certain populations such as Asians and African 
American who carry a mutated ALDH with low Km (12), 
making them theoretically ideal to examine the role of ACA. 
However, the intolerance of these individuals to ethanol 
ingestion makes it practically impossible to conduct this 
analysis. Earlier experiments that employed metabolic 
inhibitors to alter ACA levels (e.g., the ALDH inhibitor 
cyanamide) revealed the inhibitors to be nonspecific, 
ineffective, toxic and difficult to maintain in experimental 
animals (13). Due to the lack of a suitable model or method to 
assess the chronic effects of ACA, our group recently 
developed a novel transgenic mouse and a cardiac myocyte 
culture model to investigate the chronic effects of ACA on the 
heart, both in vivo and in vitro.  
 
Study of ventricular function provides the most direct evidence 
of cardiac contractile function during drug intervention or 
certain pathological conditions. Over the past decades, a 
plethora of new techniques have been established to evaluate 
the ventricular function at different levels (from 
echocardiography to single myocyte contraction). The method 
discussed here is a video-based edge-detection technique with 
simultaneous measurement of intracellular Ca
2+ homeostasis in 
isolated ventricular myocytes. 
 
MATERIALS AND METHODS 
 
Experimental Animal Models 
 
Experimental Animals and Chronic Ethanol 
Ingestion 
 
Adult Sprague-Dawley or Wistar rats are obtained as pairs of 
littermates weighing approximately 50 g and are usually used 
as described (14). All animals are housed in a temperature-
controlled room under a 12-h light/12-h dark illumination cycle 
and allowed tap water ad libitum. Animals are initially 
maintained on standard rat chow for a one-week quarantine 
period. Following the quarantine period, all animals are then 
introduced to a nutritionally complete liquid diet (Shake & 
Pour Bioserv Inc., Frenchtown, NJ, USA) for a one-week 
acclimation period (15). The use of a liquid diet is based on the 
observations made by Keane and Leonard (16) that ethanol 
self-administration resulted in less nutritional deficiencies and 
less stress to the animals in comparison to forced-feeding 
regimens, intravenous administration, or aerosolized 
inhalation. Upon completion of the acclimation period, one 
littermate is maintained on the liquid diet without ethanol, and 
the remaining littermates begin a 7-day period of ethanol 
introduction. Ethanol-consuming animals are given a diet 
containing 12%, 24%, and 36% of isocaloric ethanol on days 
1-4, 5-7 and 8, respectively. An isocaloric (250 cal/liter) pair-
feeding regimen is employed to eliminate the possibility of 
nutritional deficits. Control animals, which are randomly 
paired with the ethanol-consuming animals prior to the start of 
feeding, are provided with the equal volume of liquid diet the 
paired ethanol-consuming animals drank the day before. The 
chronic feeding usually lasts between 8 - 12 weeks. Blood 
pressure and body weight are monitored with a semi-
automated, amplified tail-cuff device (IITC Inc., Woodland 
Hills, CA) and a standard laboratory scale. The serum ethanol 
concentration is determined using a biochemistry analyzer 
(YSI 2700 Biochemistry Analyzer, Yellow Springs, OH). 
 
Transgenic Models  
 
To determine if enhanced/reduced cardiac exposure to ACA 
exacerbates/alleviates cardiac damage following chronic 
ingestion of alcohol, alcohol metabolism may be artificially 
altered in two different lines of transgenic mice to either 
increase or decrease cardiac exposure to ACA. The first 
transgene is to increase the expression of alcohol 
dehydrogenase (ADH) specifically in the heart. Increased ADH 
activity has been shown to result in greater alcohol metabolism 
and cardiac production of ACA following alcohol ingestion 
(20, 21). Our preliminary evidence demonstrates that these 
mice are markedly more sensitive than control animals to 
chronic alcohol-induced cardiac function as well as 
morphological damage (20, 21). These results indicate that 
chronic exposure to ACA, even at low levels, may be 
cardiotoxic. The results are consistent with the hypothesis that 
ACA contributes to the pathogenesis of alcoholic 
cardiomyopathy. The second transgene is to increase aldehyde 
dehydrogenase (ALDH) in the liver or non-specifically in the 
body. The liver is the prime organ for alcohol metabolism and 
breakdown of ACA into acetate via ALDH enzyme. 
Overexpression of ALDH should greatly speed up the 
breakdown of ACA, and decrease the total body burden of 
ACA, resulting in markedly reduced cardiac exposure to ACA 
following alcohol ingestion. ADH transgene has been 
constructed to produce local over-expression of ADH in the 
heart (20). This gene includes the mouse α-myosin heavy chain 
(MHC) promoter to drive cardiac specific expression. The Aberle II and Ren    3 
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cDNA for murine class I ADH (17) is inserted downstream 
from the promoter. This cDNA is chosen because class I ADH 
is the most efficient in the oxidation of ethanol. Wild-type 
mice (FVB strain) obtained from the in house colony are used 
to produce transgenic lines containing the ADH transgene (18). 
The transgenic animals are produced using standard 
procedures. For producing the ALDH transgenic mice, the 
insert will be excised and separated from the plasmid by 
KpnI/NotI restriction digestion and agarose gel electrophoresis. 
Prior to injection the insert will be purified on Qiagen 20 
columns, followed by spin gel chromatography and filtration 
through 0.22 µm filters. Approximately 100 copies of the 
purified transgene insert will be microinjected into each mouse 
embryo of the inbred strain FVB. Twenty microinjected 
embryos will be implanted into each pseudopregnant female 
and allowed to come to term. Once transgenic founders are 
identified they will maintained be on the FVB background. As 
a means of readily identifying transgenic mice, a second, 
marker transgene is coinjected with the ADH or ALDH 
transgenes into fertile embryos. The marker transgene 
expresses the tyrosinase gene in melanocytes of transgenic 
mice (19). This transgene corrects albinism since albino mice 
carry a point mutation in their endogenous tyrosinase gene. As 
FVB mice are albino this system is suitable for our transgenic 
animals. The advantages of this identification method are that 
transgenic mice can be recognized at birth by their 
pigmentation (20), most mice are spared from the trauma of 
tail clipping and an enormous amount of routine labor is saved. 
Southern blot analysis may still be required on DNA from the 
first generation of founder mice to determine copy number and 
to insure that the transgenes are intact. Considering the 
inevitable experimental and technical difficulties of 
administering ACA in vivo, these transgenic models should 
provide valid tools to assess the role of ACA in body function. 
 
Assessment of the ACA Production After Ethanol 
Challenge 
 
Cardiac tissues or ventricular myocytes (200,000 cells per ml) 
isolated from control or experimental animals with or without 
acute (30 min after 0.4 g/kg injection of ethanol) or chronic 
ethanol challenge are placed immediately in sealed vials and 
stored at -80
oC until analysis. Immediately before analysis, the 
samples are warmed to 25
oC. 2 ml of the headspace gas from 
each vial is removed through the septum on the cap with a gas 
tight syringe and transferred to a 200 µl loop injection system 
on a Hewlett-Packard 5890 gas chromatograph equipped with a 
flame ionization detector. ACA and other components are 
separated on a 9-meter VOCOL capillary column (Supelco, 
Inc.) with a 1.8 µm film thickness and an inner diameter of 
0.32 mm. The temperature is held isothermally at 30
oC, and 
helium is used as the carrier gas at a flow rate of 1.8 ml/min. 
Under the specified conditions, separation of ACA from 
ethanol and other compounds is usually complete within one 
minute. Quantification may be achieved by calibrating the Gas 
Chromatography peak areas against those from headspace 
samples of known ACA standards, over a similar concentration 
range as the cell or tissue samples, in the same buffer (21). 
 
Cell Culture Model 
 
Isolation of Ventricular Myocytes 
 
Single ventricular myocytes are isolated as described previously 
(21). In brief, animals are sacrificed after being anesthetized 
with a ketamine/xylazine solution (3:1, 1.32 mg/kg, i.p.) and 
hearts are rapidly removed and perfused (at 37
oC) with 
oxygenated (5%CO2-95% O2) Krebs-Henseleit bicarbonate 
(KHB) buffer (mM: NaCl 118, KCl 4.7, CaCl2 1.25, MgSO4 1.2, 
KH2PO4 1.2, NaHCO3 25, N-[2-hydro-ethyl]-piperazine-N’-[2-
ethanesulfonic acid] (HEPES) 10, glucose 11.1, pH 7.4. Hearts 
are subsequently perfused with a nominally Ca
2+-free KHB 
buffer for 2-3 min until spontaneous contractions ceased followed 
by a 20 min perfusion with Ca
2+-free KHB containing 223 U/ml 
collagenase (Worthington Biochemical Corp., Freehold, NJ) and 
0.1 mg/ml hyaluronidase (Sigma Chemical, St. Louis, MO). After 
perfusion, the left ventricle is removed, minced and incubated 
with the fresh enzyme solution (Ca
2+-free KHB containing 223 
U/ml collagenase) for 3-5 min. The cells are further digested with 
0.02 mg/ml trypsin (Sigma) before being filtered through a nylon 
mesh (300 µm) and collected by centrifugation (60 x g for 60 
sec). Myocytes are then resuspended in a sterile-filtered, Ca
2+-
free KHB buffer containing (in mM): NaCl 131, KCl 4, MgCl2 1, 
HEPES 10, and glucose 10, supplemented with 2% bovine serum 
albumin (BSA), with a pH of 7.4 at 37
oC. Initially, cells are 
washed with Ca
2+-free KHB buffer in order to remove any 
remnant enzyme and extracellular Ca
2+ is added incrementally 
back to 1.25 mM. 
 
Culture of Myocytes with Specific Pharmacological 
Interventions 
 
Isolated ventricular myocytes from adult normal Sprague-Dawley 
or Wistar rats maintained in a defined medium consisting of 
Medium 199 (Sigma) with Earle's salts containing HEPES (25 
mM) and NaHCO3 (25 mM), supplemented with albumin (2 
mg/ml), L-carnitine (2 mM), creatine (5 mM), taurine (5 mM), 
insulin (100 nM), penicillin (100 U/ml), streptomycin (100 
µg/ml), and gentamicin (5 µg/ml) (22). The modified culture 
medium is composed of the following per 500 ml Medium 199 
buffer: 1.0 g bovine albumin (Sigma), 0.2 g L-carnitine (Sigma), 
0.33 g creatine (Sigma), 0.31 g taurine (Sigma), 500 mg 
penicillin/streptomycin (Gibco), 2.5 mg gentamycin (Sigma), and 
1.0 ml (10
-7 M) insulin. Myocytes are normally cultured in 2 ml 
medium in sealed vials with silicone septa (VWR product 
number 15900-008) for 4 - 6 hours with ACA (µM or mM 
ranges) or specific pharmacological intervention before 
mechanical and intracellular Ca
2+ properties are evaluated. Our 
earlier studies failed to observe any noticeable mechanical effect 
from ACA at concentration below low mM range in either Aberle II and Ren    4 
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cardiac tissues or myocytes (7, 10), which may be due to the 
volatile  property of ACA in open air. In some studies, the 
myocytes are co-incubated with the lipid peroxidation inhibitor, 
butylated hydroxytoluene (20 µM), the CYP2E1 inhibitor diallyl 
sulfide (100 µM), the xanthine oxidase inhibitor allopurinol (100 
µM) or the aldehyde oxidase inhibitors menadione (50 – 100 
µM) and chlorpromazine (100 µM). The cells are maintained at 
37
oC in an incubator with 100% humidity and 5% CO2. 
Mechanical properties have been shown to remain relatively 
stable in myocytes within 12-24 hr in the serum-free medium. 
Only rod-shaped myocytes with clear edges are selected for 
recording of mechanical properties or intracellular Ca
2+ 
transients. Our preliminary data revealed that ACA at µM range 
depresses myocyte contractile function possibly through ethanol-
inducible form of cytochrome P-450 oxidase (CYP2E1), xanthine 
oxidase and lipid peroxidation (23). 
 
Mechanical and Functional Characterization 
 
Cell Shortening/Relengthening Measurements 
 
Mechanical properties of ventricular myocytes are assessed 
using an IonOptix MyoCam® video-based system (IonOptix 
Co., Milton, MA) as described
 (24). In brief, coverslips with 
cells attached are placed in a chamber mounted on the stage of 
an inverted microscope (IX-70) and superfused (∼2 ml/min at 
25
oC) with a buffer containing (in mM): NaCl 131, KCl 4, 
CaCl2 1, MgCl2 1, glucose 10, HEPES 10, at pH 7.4. The cells 
are field-stimulated at a frequency of 0.5 Hz, 3 msec in 
duration. A video-based edge-detector is used to capture and 
convert changes in cell length during shortening and 
relengthening into an analogue voltage signal. Cell shortening 
and relengthening are assessed using the following indices: 
peak shortening (PS), time-to-90% PS (TPS) and time-to-90% 
relengthening (TR90), maximal velocities of shortening 
(+dL/dt) and relengthening (-dL/dt), respectively.  
 
Intracellular Ca
2+ Transient Measurement 
 
Myocytes are loaded with fura-2/AM (0.5 µM) for 10 min at 
25
oC. Fluorescence measurements are recorded with a dual-
excitation single-emission fluorescence photomultiplier system 
(IonOptix). Myocytes are placed on an inverted microscope 
and imaged through an Olympus Fluor 40x oil objective. 
Myocytes are exposed to light emitted by a 75 W halogen lamp 
through either a 360 or 380 nm filter while being stimulated to 
contract at 0.5 Hz. Fluorescence emissions are detected 
between 480-520 nm by a photomultiplier tube after initial 
illumination at 360 nm for 0.5 sec and then at 380 nm for the 
duration of the recording protocol. The 360 nm excitation scan 
is repeated at the end of the protocol and qualitative changes in 
intracellular Ca
2+ concentration ([Ca
2+]i) is inferred from the 
ratio of the fura-fluorescence intensity (FFI) at both 
wavelengths. Fluorescence decay time (τ) is also measured as 
an indication of the intracellular Ca
2+ clearing rate (24). 
 
Evaluation of the Function of Sarco(endo)plasmic 
Reticulum Ca
2+-ATPase (SERCA) 
 
In order to assess the SERCA-mediated cytosolic Ca
2+ 
clearing, the previously described protocol (25) is followed. 
After steady-state myocyte contraction had been established, 
sarcoplasmic reticulum (SR) release is initiated by a brief (100 
ms) and rapid introduction of caffeine (10 mM). The 
introduction of caffeine is under a Na
+- and Ca
2+-free solution 
(0Na
+/0Ca
2+). This maneuver should prevent the extrusion of 
Ca
2+ through Na
+-Ca
2+ exchanger (NCX). The parameters by 
which SR function is assessed are SR Ca
2+ release (measured 
by area of cell shortening phase normalized to peak shortening 
amplitude, AS/PS) and SR Ca
2+ uptake (area of cell 
relengthening phase normalized to peak shortening amplitude 
AR/PS).  
 
Evaluation of Na
+/Ca
2+ Exchanger (NCX) Function 
 
To evaluate the function of NCX in cardiomyocytes, the 
myocytes are exposed myocytes to a long caffeine protocol. 
Throughout the continuous caffeine application, SR Ca
2+ 
uptake is functionally disabled since caffeine prevents SR Ca
2+ 
accumulation (25, 26). Therefore, the intracellular Ca
2+ 
transient decline primarily depends on NCX and slow 
processes such as mitochondrial Ca
2+ uptake and sarcolemmal 
(SL) Ca
2+ATPase (27), in the presence of extracellular Na
+ and 
Ca
2+ (control buffer with 10 mM caffeine). After the repeated 
long caffeine exposure (after re-establishing steady-state 
contraction), in the presence of 5 mM Ni
2+ blocks the extrusion 
of Ca
2+ through NCX. Under these conditions, cytosolic Ca
2+ 
clearance primarily depends on the slow processes. The 
quantification NCX-dependent Ca
2+ clearance is measured as 
differences between areas underneath the twitch curve 
(normalized to peak shortening amplitude) before and after 
application of Ni
2+.  
 
Biochemical Evaluations of Cardiac Damage 
 
Preparation of Mitochondrial Fraction 
 
Myocardial tissue specimens
  (70 to 80 mg) are minced and 
homogenized at 4°C for 30
 sec in 12 volumes of HES buffer, 
which
  consisted of 10 mM HEPES-NaOH (pH 7.4), 1 mM 
EDTA, and
 250 mM sucrose, in a glass homogenizer with a 
Teflon pestle.
 The homogenate produced is then centrifuged at 
4°C and 700g for 10 minutes
 in order to remove any nuclear 
and myofibrillar debris, the resultant
 supernatant is centrifuged 
at 7000g for 10
 minutes. The pellet is resuspended and washed
 
3 times with HES buffer (28).
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Measurement of Mitochondrial Respiration 
 
Mitochondrial respiration is measured using an oxygen 
electrode (YSI International) and oxygen consumption 
chamber (Gibson Medical Electronics). Experiments are 
performed at 37
oC. The assay medium contained 125 mM KCl, 
5 mM MgCl2, 2 mM KPO4 amd 5 mM HEPES-KOH (pH 7.4). 
Mitochondria are diluted to 0.1 mg/ml. Complex I linked (5 
mM glutamate) and complex II-linked substrates (5 mM 
succinate with 1 µg/ml rotenone) are use for investigations. 
State 3 respiration is measured for 2 min following the addition 
of ADP (1 mM). The individual respiratory complexes (I-V) 
are measured as described previously (29, 30).  
 
Oxidative Stress Status - Glutathione Assay 
 
Glutathione levels are determined in cardiac cells and tissues 
as an indication of oxidative stress. Glutathione peroxidase 
catalyzes the reduction of lipid hydroperoxides or hydrogen 
peroxide using reduced glutathione (GSH) as substrate, thus 
providing a line of protection against oxidative stress and lipid 
peroxidation. GSH is regenerated by the reduction of 
glutathione disulfide (GSSG) through the catalytic action of 
glutathione reductase. A low ratio of GSH/GSSG suggests 
enhanced oxidative stress. GSH and GSSG levels are measured 
according to the method described by Griffith (31). Tissues are 
washed with PBS buffer and 5 mM EDTA. For measurement 
of GSH, frozen tissue samples are homogenized in 4 volumes 
(w/v) of 1% picric acid. Acid homogenates are centrifuged at 
16,000 x g (30 minutes) and supernatant fractions collected. 
Supernatant fractions are assayed for total GSH and GSSG by 
the standard recycling method (31) and GSH content is 
determined using a standard curve generated from known 
concentrations of GSH. The procedure consisted of using one-
half of each sample for GSSG determination and the other half 
for GSH. Samples for GSSG determination are incubated at 
room temperature with 2 µl of 4-vinyl pyridine (4-VP) per 100 
µl sample for 1 hour after vigorous vortexing. Incubation with 
4-VP conjugates any GSH present in the sample so that only 
GSSG is recycled to GSH in the recycling assay. This allowed 
for measurement of only GSSG without interference by GSH. 
The GSSG (as GSHx2) is then subtracted from the total GSH 
to determine actual GSH level.  
 
Fluorescent Detection of Reactive Oxygen Species 
 
2',7'-Dichlorofluorescein (DCF) can be used as a measure of 
the oxidative stress in myocyte (32). DCF diacetate (DCFDA) 
will be added to cells of interest for 30 min. DCFDA is 
prepared in ethanol and diluted into myocyte culture medium 
to a final concentration of 5 mM. DCFDA is taken up by cells 
and on deacetylation forms a nonfluorescent DCF. Upon 
oxidation, this becomes DCF. Myocytes are trypsinized but not 
fixed, and the mean fluorescence is measured for 10,000 cells 
using a Becton Dickinson FACScan with excitation at 488 nm 
and emission at 530 nm (± 21 nm). 
 
Lipid Peroxidation  
 
In order to assess lipid peroxidation, malondialdehyde (MDA) 
and 4-Hydroxy-2-nonenal (4-HNE) levels, end products of 
lipid peroxidation, are measured in the cells from in vivo and in 
vitro studies. A colorimetric assay (LPO-586 Kit; Oxis 
International) that is based on the method of Esterbauer et al. 
(33) is used to determine levels of lipid peroxidation. The 
protein concentration is determined using the Bradford method. 
Protein samples are stored at -70
oC until analysis. In 200 µl of 
sample, 10 µl of 0.5 M BHT and 650 µl of Reagent 1 is added. 
The tubes are vortexed and 150 µl of 15.4 M methanesulfonic 
acid (Reagent 2) is added to the tubes. Samples are then 
incubated at 45
oC for 45 min, which is followed by 
centrifugation for 10 min at 15,000 x g. The resultant clear 
supernatant is transferred to a cuvette and the absorbance is 
measured at 586 nm (color is stable for 1 hour at room 
temperature). Each assay that is performed also included 
sample blanks, reagent blanks and MDA and 4-HNE standards. 
The analyte concentration in each sample is calculated using 
the molar extinction coefficient at 586 nm of 110,000. 
 
Protein Carbonyl Assay 
 
To assess the oxidative protein damage specific to the heart, 
the carbonyl content of protein extracted from mitochondria 
and used for analysis (34). Briefly, proteins are extracted and 
lysed to prevent proteolytic degradation. Nucleic acids are 
eliminated by treating the samples with 1% streptomycin 
sulfate for 15 min, followed by a 10 min centrifugation (11,000 
x g). Protein is precipitated by adding an equal volume of 20% 
TCA to protein (0.5 mg) and centrifuged for 1 min. The TCA 
solution is removed and the sample resuspended in 10 mM 2,4-
dinitrophenylhydrazine (2,4-DNPH) solution. Samples are 
incubated at room temperature for 15-30 min. 500 µl of 20% 
TCA is added and samples centrifuged for 3 min. The resultant 
supernatant is discarded, the pellet washed in ethanol:ethyl 
acetate and allowed to incubate at room temperature for 10 
min. The samples are centrifuged again for 3 min and the 
ethanol:ethyl acetate steps are repeated 2 more times. The 
precipitate is resuspended in 6 M guanidine solution, 
centrifuged for 3 min and insoluble debris removed. The 
maximum absorbance (360-390 nm) is read versus the 
appropriate blanks (2 M HCl) and the carbonyl content 
calculated using the molar absorption coefficient of 22,000 M
-1 
cm
-1. 
 
HNE-Protein Adduct Immunoreactivity  
 
HNE, a major component of lipid peroxidation, has been 
shown to react with proteins to form HNE-protein adducts. 
HNE-protein adducts are relatively stable and can be used as a Aberle II and Ren    6 
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marker of radical-mediated oxidative stress and tissue/cell 
damage. HNE-protein adduct formation is increased under 
chronic alcoholism (35). Therefore, it may be helpful to 
measure HNE-protein adducts under ACA-induced cardiac 
damage. The formation of reducible HNE-protein adducts 
(Michael or imine adducts) can be measured using an ELISA 
method as described (36). Mitochondria are thawed, then 
diluted to 0.02 mg/ml in 50 mM phosphate buffer at pH 7.4, 
and subsequently boiled for 5 min. 50 µl of each sample is 
added to the well of a 96-well microplate, and the protein is 
allowed to bind for 1 hour at 37
oC. Phosphate buffer is used to 
rinse the wells, which are then treated with 100 µl of 50 mM 
NaBH4 for another hour at 37
oC to reduce further HNE-protein 
adduct formation. The well is blocked for 30 min and 
subsequently incubated for 1 hour at 37
oC with rabbit antibody 
672, which recognizes the reduced HNE-protein adduct. The 
well is washed and incubated with an alkaline phosphatase-
conjugated goat anti-rabbit antibody (Bio-Rad), and then 
developed using p-nitropheny1 phosphate (Sigma Chemical, 
St. Louis, MO). 
 
RESULTS AND DISCUSSION 
 
The metabolism of ethanol within the body has been 
investigated and identification of the pathway is useful for the 
purposes of further investigation. After ethanol is absorbed into 
the cells, it is converted into ACA by ADH in the cytosol. The 
ACA that is present is further oxidized into acetate by ALDH 
within the mitochondrial matrix. Both of these oxidation 
reactions yield the production of one equivalent NADH (Fig. 
1). 
 
 
Fig. 1: The metabolic pathways of ethanol and ACA (courtesy of Dr. Shannon 
Bailey at University of Alabama at Birmingham). 
 
The above pathway results in the production of free radicals 
predicated upon changes in NADH amounts and NADH/NAD
+ 
redox ratios (37). These increases alter the activity of xanthine 
oxidase, which generates free radicals. Another pathway of 
ethanol metabolism is the microsomal ethanol oxidizing 
system (MEOS), which catalyzes the conversion of ethanol to 
ACA. In chronic situations, it has been shown that the 
metabolism of ethanol shifts from the ADH pathway, to one 
involving the MEOS, and CYP2E1 (38). In the chronic state, 
the levels of MEOS and CYP2E1 have been shown to be 
elevated (39). The activation of CYP2E1 by ethanol is one of 
the main metabolic pathways for ethanol which is responsible 
for the production of oxidative damage in hepatocytes (40). 
Also, CYP2E1 is expressed constitutively in isolated rat 
cardiomyocytes (41). Increased lipid peroxidation and 
CYP2E1 levels have been observed following chronic ethanol 
administration. This is consistent with the finding that 
enhanced lipid peroxidation following ethanol ingestion may 
be prevented with the use of CYP2E1 inhibitors (42). In 
addition, ethanol may also lead to oxidative insults via a 
reaction involving aldehyde oxidase with ACA or NADH, 
which can dysregulate mitochondrial oxidative metabolism 
(36). The electron transport chain within the mitochondria 
contributes significantly to the production of reactive oxygen 
species (ROS), and exposure of ethanol augments the ROS 
production, which may further be exacerbated by a decrease in 
mitochondrial antioxidant defenses (43). 
 
For the purposes of investigating the effects of ethanol and 
ACA, there are several inhibitors that may be employed. Two 
such inhibitors that may be utilized in investigation are 4-
methylpyrazole (4-MP), a selective ADH inhibitor (44), and an 
ALDH inhibitor, cyanamide (21). Diallyl sulfide, a CYP2E1 
inhibitor, may be useful for the assessment of ethanol/ACA 
(40). As previously mentioned, aldehyde oxidase and xanthine 
oxidase are both involved in the metabolism of ethanol and 
ACA, and result in oxidative stress leading to cardiac 
mechanical dysfunction. As indicated in Fig. 2, both aldehyde 
oxidase and xanthine oxidase may be intervened 
pharmacologically with menadione and allopurinol, 
respectively. 
 
 
Fig. 2: Pharmacological interventions to examine the mechanisms of action 
involved in the cardiac toxicity of ACA. 
 
One of the main benefits of the in vitro myocyte culture 
method is that the effect of ACA on cardiac excitation-
contraction coupling may be examined with the assistance of 
specific pharmacological interventions for ACA metabolism. 
The aforementioned inhibitors of the ethanol/ACA metabolic 
pathway or sources of free radical generation may be added to 
the culture dishes instead of employing chronic feeding 
regimen for in vivo analysis. Another advantage is the ease 
with which drug interactions may be studied. People with 
alcohol abuse often use or abuse other drugs that may affect 
the pharmacokinetics of ethanol, for example, it is reported that Aberle II and Ren    7 
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30¯60% of alcoholics consume cocaine (45). Despite the 
evidence of multiple usage of drugs is involved along with 
alcohol consumption, little research has been done to 
understand the drug interactions. Another example for drug 
interaction is the combinatorial effects of nicotine (smoking) 
and alcohol. Ethanol and nicotine may synergistically increase 
heart rate (46), although the mechanism of action remains to be 
elucidated. The use of specific inhibitors in an in vitro 
experimental setting (such as the one described in this 
manuscript) should be able to provide valuable information 
regarding the combined effects and interactions of other drugs 
associated with alcohol usage. Development of an in vitro 
method regarding the use of ACA allows these interactions to 
be studied in a reliable manner that does not involve a time-
consuming  in vivo feeding regimen. In addition, parameters 
such as interstitial materials, nerve fibers, and other cells, 
which are often present in the setting of in vivo should be 
eliminated using the in vitro culture method. The presence of 
heterogeneous cell types, such as fibroblasts, and nerve 
terminals that occur in multicellular preparations like papillary 
muscles can make experimental results difficult or impossible 
to interpret. The mechanical function of the myocytes may be 
affected by non-myocyte components such as the coronary 
vasculature and/or interstitial connective tissue. For example, it 
is possible that the modulations in the contractile performance 
under ethanol exposure may not be due to actual reduced 
function of the myocyte, but rather due to increased interstitial 
fibrosis. Therefore, it is necessary that there are methods 
available for scientists to study the smallest cardiac contractile 
unit - ventricular myocytes specifically, independent of any 
surrounding factors. However, there are drawbacks to this cell 
culture model as with all the in vitro study, e.g., lack of the 
physiologic environment which would otherwise be present in 
an  in vivo setting. In response to this deficit, the 
aforementioned ADH and ALDH transgenic models should be 
useful for interpretation of the cardiac effects of ACA, in 
conjunction with our in vitro cell culture model. 
 
Synopsis 
 
Alcohol abuse continues to remain as a prevalent social 
problem contributing to severe heart problems in alcoholics. It 
is a current opinion that the toxic effects of alcohol on the heart 
are attributable, in large part, to the first metabolic product of 
ethanol - ACA. ACA is formed from the breakdown of ethanol 
in cells and is far more toxic and reactive than ethanol. In order 
to better understand the adverse repercussions of chronic 
alcohol abuse, assessment of cardiac toxicity of ACA using our 
described methods should lead to useful clues regarding the 
pathogenesis of alcoholic cardiomyopathy. 
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PROTOCOLS 
 
Protocols for isolation of ventricular myocytes and measurement of myocyte mechanics has been described in detail in our previously 
published article as the following: Ren J, Wold LE. Measurement of cardiac mechanical function in isolated ventricular myocytes from 
rats and mice by computerized video-based imaging. Biol Proced Online 3: 43-53, 2001. Please refer for detail. The following lists 
additional protocols described in this manuscript.  
 
Evaluation of the Function of Sarco(endo)plasmic Reticulum Ca
2+-ATPase (SERCA) 
 
1.  Make the fluo-3AM stock solution as follows: 
     
•  5 µl 1M fluo stock 
•  1 µl pluronic solution 
•  5 ml contractile buffer (from the stock below) 
•  0.05 g Albumin 
 
2.  Prepare the following perfusates: 
 
Contractile buffer    300ml HEPES 
0.54 g Glucose 
300 µl 1 M CaCl2 
0 Ca
2+ buffer  50 ml HEPES 
0.09 g Glucose 
Lithium buffer no Ca
2+  50 ml Lithium stock 
0.09 g Glucose 
Lithium buffer + Caff  10 ml Lithium stock 
0.018 g Glucose 
0.019 g Caffeine 
 
3.  Fill the four chambers with the above solutions and remove all air bubbles in the tubing. 
4.  Load a plate of cells with fluo-3AM by removing the contractile buffer and replacing with fluo-3AM. Load for 30 minutes. 
After loading, wash the cells 2-3 times with contractile buffer. 
5.  Isolate a cell in the viewer and make sure that the electrically stimulated (ES) fluo trace has little background noise. 
6.  Record four ES fluo traces. 
7.  Switch the perfusate to the Ca
2+-buffer and allow perfusion for 15 seconds. Once the cell stops contracting, turn off the 
electrical stimulus (ES). 
8.  Switch the perfusate to Lithium buffer with 0 Ca
2+ and perfuse for 15 seconds. (No ES). 
9.  Once the program begins recording, perfuse the cell with a 100 msec puff of the Lithium buffer plus caffeine. 
10.  Wash the cells with contractile buffer for 1-2 minutes before finding another cell on the same plate. 
11.  Record 5-6 traces per well. 
 
Evaluation of Na
+/Ca
2+ Exchanger (NCX) Function 
 
1.  Make the fluo-3AM stock solution as follows: 
 
•  5 µl 1M fluo stock 
•  1 µl pluronic solution 
•  5 ml contractile buffer (from the stock below) 
•  0.05 g Albumin 
 
2.  Prepare the following perfusates: 
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Contractile buffer (4)    200 ml HEPES 
0.36 g Glucose 
200 µl 1M CaCl2 
Contractile + Caff (1)  10 ml contractile buffer 
0.019 g Caffeine 
Contractile + Ni (3)  50 ml contractile buffer 
250 µl 1M NiCl2 
Contractile + Caff+ Ni (2)  10 ml contractile buffer 
0.019 g Caffeine 
50 µl 1M NiCl2 
 
3.  Fill the four chambers with the above solutions and remove all air bubbles in the tubing. 
4.  Load a plate of cells with fluo-3AM by removing the contractile buffer and replacing with fluo-3AM. Load for 30 minutes. 
After loading, wash the cells 2-3 times with contractile buffer. 
5.  Isolate a cell in the viewer and make sure that the electrically stimulated (ES) fluo trace has little background noise. 
6.  Record four ES fluo traces. 
7.  Turn the ES off for 30 seconds. 
8.  Perfuse the cell with contractile buffer plus caffeine for 6 seconds. Once the fluo trace returns to baseline, perfuse with 
contractile buffer. 
9.  Allow the cell to recover for 1-2 minutes. Try recording a baseline fluo-3 trace to see if the background is noisy. 
10.  Record four ES fluo traces (on the same cell as before). 
11.  Switch the perfusate to contractile buffer plus nickel for 15 seconds. Once the cell stops twitching, turn the ES off. 
12.  Switch the perfusate to contractile buffer plus nickel plus caffeine and perfuse for 6 seconds. 
13.  Wash the plate of cells for 1-2 minutes before finding another one. The protocol can be repeated 4-5 times on the same well of 
cells. 
 
Oxidative Stress Status - Glutathione Assay 
 
1.  Preparing samples 
 
•  Measure out about 0.050 grams of frozen tissue. Put the sample in a clearly labeled        1ml micro-centrifuge tube. Keep 
all tubes on ice at all times. 
•  Take the weight of the sample and multiply it by 4000.  
•  This is the amount in µl of picric acid you should add to each tube. 
•  Sonicate each tube for 5-15 seconds. 
•  Centrifuge each tube at 13,500 rpm for 20 minutes. 
•  Take off the supernatant and place it in another clearly labeled tube.  
•  These samples can be frozen in the -80
oC freezer until a later time. 
 
2.  Assay Procedures 
 
Figure out how many cuvettes you will need to do your samples in triplicate, twice. One for GSH and another for GSSG. This will 
give you how much buffer you will need to do the assay to avoid wasting reagents. 
 
Example:    NADPH      150 samples X 0.350ml = 52.5ml of buffer needed. 
       DTNB         150 samples X   0.05ml = 7.5ml of buffer needed.  
       GR             150 samples X   0.025ml = 3.75ml of buffer needed. 
 
Be sure to round up number of samples and account for extra ml needed to calculate the standard curve. 
 
3.  Buffers 
 
•  125mM Phosphate/EDTA buffer: 
  Mono (500ml):  0.125M X 0.5L X 138.0(F.W.) = 8.625g 
  Di (500ml):  0.125M X 0.5L X 142.0(F.W.) = 8.875g 
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•  EDTA buffer: (500ml) 
  0.0063M X 0.5L X 372.24(F.W.) =1.173g 
 
•  Add 1.173 of EDTA buffer to the mono buffer and another 1.173g to the di buffer.  
Stir each solution for 25-30 minutes. 
Pour 500-600mL of the di buffer into a 1000mL beaker. Add the mono buffer to the di buffer until the pH of the 
combined buffers is 7.5. Pour buffer into bottle labeled Phosphate/EDTA. 
 
•  0.3mM NADPH buffer:  (350 µl) 
  0.0003M X liters of buffer needed calculated above (ex. 0.0525L) X 833(F.W.) = number of grams. 
 
•  6mM DTNB buffer:  (50 µl) 
  0.006M X liters of buffer needed calculated above (ex. 0.0075L) X 396.4(F.W.) = number of grams. 
 
•  Add the number of grams of NADPH and the number of grams of DTNB to the amount of Phosphate/EDTA buffer 
needed which was calculated in the example. Put this in a jar or a container which can be kept cold and in the dark. This 
will be the mix buffer.  
 
•  GR  Each time you open up a new lot number or sample the dilution will be different.  
            2500 unit= 1:50 dilution. 3.75ml/50= 75 µl GR in 3.765ml mix buffer 
            500 unit= 1:10 dilution. 3.75 ml/10= 375 µl GR in 3.375ml mix buffer 
            600 unit= 1:200 dilution. 3.75ml/200= 18.75 µl in 3.731ml mix buffer 
       Place the solution in a small falcon tube that should be kept cold. 
 
4.  Standard Curve Mix 
 
GSH:  start with 10mM stock = 0.0030703g in 1mL H2O 
        1mM = 100 µl of 10mM in 900 µl H2O 
        0.1mM = 100 µl of 1mM in 900 µl H2O 
        0.01mM = 100 µl of 0.1mM in 900 µl H2O 
        0.002mM = 10 µl of 0.01mM in 40 µl H2O 
 
•  be sure to change tips of pipette between each addition and mix each solution 
 
Conditions:  The system is run at 30
o C. Run for 5 minutes. Read at 412nm. 
 
Standard Curve 
 
Table 1: 
Mix Buffer  H2O GSH  GR 
400ul   200mM    70  µl 5  µl 25  µl 
  0.01mM  70  µl   5  µl 
65   10 
55   20 
45   30 
35   40 
25   50 
  
  0.1  mM   
70 µl   5  µl 
65   10 
 
  
Blank     
400 µl 75  µl     0 µl    
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Figure standard curve on the computer template (Cricket Graph). Take the Blank and subtract from all the standards and graph a 
curve. The curve must be linear to continue on to the sample. (0.990 or better) 
 
5.  Samples 
 
Table 2: 
Mix  buffer    H2O     S a m p l e       G R  
400ul     70  µl    5  µl    25  µl 
 
Add the GR last because this is what starts the reaction.  
If the count is higher or lower than the top or bottom of the curve, you must adjust your sample to get it within the curve. 
 
6.  GSSG 
 
This is run after GSH and is done by adding Vinyl Pyridine to each of the samples. (1 µl of VP to 50 µl of sample, vortex and let sit 
for 1 hour in fridge before you run on spec.)  Run the samples the same as you ran the GSH samples. 
 
Table 3: 
M i x      H 2O    VP  sample   GR 
400 µl        7 0   µl      5  µl      25  µl  
 
Protein Carbonyl Assay 
 
1.  A 200 mg tissue sample is finely minced in 3 ml of Lysis buffer and is incubated at room temperature for 15 min. The 
supernatant is then transferred to an Eppendorf tube and centrifuged at 6,000 x g for 10 min. Pellet is left behind. 
2.  Two tubes of samples are prepared for each extracted protein with 500 µl in each tube. 500 µl of 20% TCA is added to each 
tube to precipitate the protein. Samples are incubated on ice for 10 min and centrifuged at 11,000 x g for 5 min using a table 
top centrifuge. 
3.  Discard supernatant and add 500 µl 2 M HCl to one tube (serves as blank for that sample) and add 500 µl 10 mM 2,4, DNPH 
(dinitrophenylhydrazine, dissolved 2.5 M HCl) to the other tube. 
4.  Incubate the tubes in the dark for 1 hour, with vortexing every 15 min. 
5.  At the end of 1 hour, add 500 µl 20% TCA to each tube and centrifuge 11,000 x g for 3 min at room temperature. 
6.  Remove supernatant and wash pellet with Ethanol/Ethyl acetate wash (1:1) incubate for 10 min. Then centrifuge 11,000 g for 
3 min at room temperature, repeat 2 more times to wash pellet. 
7.  After the last wash, add 600 µl 6 M Guanadine HCl to pellet and incubate at 37
oC for 30 – 60 min to dissolve pellet, centrifuge 
11,000 x g for 1 min to remove insoluble debris. 
8.  Read the clear supernatant at 360 nm (spectrophotometer may be set to scan 360 – 390 nm wavelength).  
9.  Bradford the final sample blanks (usually 1:200 dilution). Use the 6 M Guanadine HCl for standard with the BSA solution. 
10.  The final protein carbonyl content = Absorption at 360 nm X 45.45 nmol/ml /protein content (mg). 